MGC Pharmaceuticals Limited (MGCLF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
MGC Pharmaceuticals Limited (MGCLF) trades at $0.27 with AI Score 46/100 (Grade C). MGC Pharmaceuticals Limited is an Australian biopharmaceutical company focused on developing and distributing plant-derived medicines, including medical cannabis products and botanical therapeutics. Market cap: $12.11M, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for MGCLF: MGCLF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MGCLF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MGCLF: the 1 perspectives are evenly split.
How is this calculated? →MGC Pharmaceuticals Limited (MGCLF) Healthcare & Pipeline Overview
MGC Pharmaceuticals Limited is a West Perth, Australia-based biopharmaceutical company specializing in plant-derived medicines, including medical cannabis and botanical therapeutics. The firm is advancing a pipeline of investigational drug candidates through clinical trials, targeting conditions like COVID-19, epilepsy, and dementia, alongside offering a range of commercial products.
What Is the Investment Thesis for MGCLF?
MGC Pharmaceuticals Limited (MGCLF) presents a research-stage biopharmaceutical profile centered on plant-derived medicines, with a market capitalization of $12.11M. The company's investment thesis is primarily driven by the progression of its clinical pipeline, which includes CimetrA in Phase III trials for COVID-19, CannEpil in Phase IIb for drug-resistant epilepsy, and CogniCann in Phase II for dementia. Successful advancement and regulatory approval of these candidates would be significant value drivers. The company's gross margin stands at 38.0%, indicating a positive margin on its products, though it currently operates at a substantial profit margin of -614.6%, reflecting its development-stage nature and ongoing R&D investments. The growing acceptance and research surrounding medicinal cannabis and botanical therapeutics globally represent a favorable industry backdrop. However, the company's OTC Other tier listing indicates a higher risk profile due to less stringent disclosure requirements and potential liquidity challenges. Monitoring clinical trial outcomes, regulatory milestones, and the company's path to profitability are crucial for assessing its long-term potential.
Based on FMP financials and quantitative analysis
MGCLF Key Highlights
- Market Capitalization: MGC Pharmaceuticals Limited has a market capitalization of $12.11M, reflecting its current valuation as a development-stage biopharmaceutical company.
- Profitability: The company reported a profit margin of -614.6%, indicating significant net losses as it continues to invest heavily in research and development for its drug pipeline.
- Gross Margin: A gross margin of 38.0% suggests that the company's core products and services generate a positive margin before operating expenses, covering direct costs of goods sold.
- Beta: With a Beta of 0.97, MGCLF's stock price tends to move largely in line with the broader market, indicating moderate volatility relative to market benchmarks.
- Clinical Pipeline: The company is actively advancing multiple drug candidates, including CimetrA in Phase III, CannEpil in Phase IIb, and CogniCann in Phase II, which are critical for its future growth and valuation.
Who Are MGCLF's Competitors?
MGCLF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MGCLF's Key Strengths?
- Diverse clinical pipeline addressing significant medical needs (COVID-19, epilepsy, dementia).
- Expertise in plant-derived medicines and phytocannabinoid development.
- Established commercial product lines (ArtemiC) providing current revenue streams.
- Global focus with headquarters in Australia and international development efforts.
- Consulting services leverage internal R&D capabilities for additional revenue.
What Are MGCLF's Weaknesses?
- Significant negative profit margin (-614.6%) indicating substantial losses.
- Reliance on successful, costly, and lengthy clinical trial outcomes for future profitability.
- OTC Other tier listing may imply lower liquidity and less stringent disclosure requirements.
- Relatively small market capitalization ($0.01B) compared to larger pharmaceutical players.
- No dividend yield, indicating no current return to shareholders beyond potential capital appreciation.
What Could Drive MGCLF Stock Higher?
- Successful completion and positive data readout from the Phase III clinical trial for CimetrA in early-stage COVID-19 treatment, potentially leading to regulatory submission.
- Advancement of CannEpil from Phase IIb to Phase III clinical trials for drug-resistant epilepsy, signaling progress towards commercialization.
- Positive interim or final results from the Phase II clinical evaluation of CogniCann for symptomatic relief of dementia, supporting further development.
- Expansion of the ArtemiC product line's market reach or introduction of new commercial botanical therapeutics, contributing to revenue growth.
- Formation of strategic partnerships or licensing agreements for its drug candidates or commercial products, potentially providing non-dilutive funding or market access.
What Are the Key Risks for MGCLF?
- Financial-distress signal — its Altman Z-Score of -16.13 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- The company's significant negative profit margin of -614.6% indicates substantial ongoing losses, raising concerns about long-term financial sustainability without further capital infusions.
- Clinical trial failures or delays for CimetrA, CannEpil, or CogniCann could severely impact the company's valuation, future revenue potential, and ability to attract investment.
- Being listed on the OTC Other tier implies higher liquidity risk, wider bid-ask spreads, and potentially less transparent financial reporting, which can deter institutional investors.
- Regulatory changes or increased scrutiny in the medical cannabis and botanical therapeutics industry could negatively affect product development, approval, and market access.
- Intense competition from larger, more established pharmaceutical companies with greater resources for R&D and market penetration poses a significant challenge to market share acquisition.
What Are the Growth Opportunities for MGCLF?
- Advancement of CimetrA to Market: The progression of CimetrA through Phase III clinical trials for early-stage COVID-19 represents a significant growth opportunity. Successful completion of trials and subsequent regulatory approval could enable MGC Pharmaceuticals to tap into the global market for antiviral and anti-inflammatory treatments. The market for COVID-19 therapeutics, while evolving, continues to be substantial, particularly for treatments addressing early disease stages. A successful launch could provide a near-term revenue stream and validate the company's drug development capabilities, potentially within the next 1-3 years.
- Commercialization of CannEpil for Epilepsy: CannEpil, currently in Phase IIb trials for drug-resistant epilepsy, targets a patient population with limited effective treatment options. The global market for epilepsy therapeutics is projected to grow, driven by increasing prevalence and demand for novel therapies. Successful clinical development and regulatory approval of CannEpil would allow MGC Pharmaceuticals to enter a specialized, high-value segment of the neurological disorder market. This represents a mid-to-long-term growth driver, with potential market entry in 3-5 years, contingent on trial success.
- Development of CogniCann for Dementia: CogniCann, in Phase II clinical evaluation for symptomatic relief of dementia, addresses a major global health challenge with a rapidly aging population. The market for dementia treatments is enormous, though current therapeutic options are limited primarily to symptomatic management. If CogniCann demonstrates efficacy and safety in further trials, it could position MGC Pharmaceuticals as an innovator in a high-need area. This is a longer-term growth opportunity, likely requiring 5+ years for full development and regulatory pathways.
- Expansion of ArtemiC Product Line: Beyond its pharmaceutical pipeline, MGC Pharmaceuticals offers the ArtemiC product line, alongside other cannabinoid-focused and non-pharmaceutical goods. Expanding the reach and product offerings within this commercial segment could provide more immediate revenue growth and diversify the company's income streams. Leveraging existing distribution channels and exploring new markets for these products could capitalize on the increasing consumer interest in natural health solutions and botanical supplements, offering ongoing growth potential.
- Leveraging Expertise in Clinical Research Consulting: MGC Pharmaceuticals extends its services to include consulting, particularly in clinical research. As a company with active clinical trials and experience in plant-derived medicine development, it possesses specialized knowledge. Expanding this consulting arm could generate additional revenue by assisting other companies in navigating the complexities of clinical development, especially within the niche of botanical and cannabinoid therapeutics. This leverages existing internal capabilities and offers a scalable service-based revenue opportunity in the short to medium term.
What Opportunities Does MGCLF Have?
- Growing global acceptance and research into medicinal cannabis and botanical therapeutics.
- Potential for CimetrA to address ongoing demand for COVID-19 treatments.
- Addressing unmet medical needs in drug-resistant epilepsy and dementia with pipeline candidates.
- Expansion of commercial product lines into new markets or with new offerings.
- Strategic partnerships or collaborations to accelerate drug development and market access.
What Threats Does MGCLF Face?
- High regulatory hurdles and lengthy approval processes for pharmaceutical products.
- Intense competition from established pharmaceutical companies and other biotech firms.
- Clinical trial failures or delays could significantly impact company valuation and solvency.
- Evolving and potentially restrictive regulations in the medical cannabis industry.
- Capital raising challenges due to development-stage nature and OTC listing.
What Are MGCLF's Competitive Advantages?
- Proprietary clinical pipeline of plant-derived drug candidates (CimetrA, CannEpil, CogniCann) in various trial phases.
- Specialized expertise in the development and manufacturing of phytocannabinoid-derived medicines.
- Established intellectual property and know-how in botanical therapeutics formulation and delivery.
- Regulatory experience gained from advancing drug candidates through clinical trial processes.
- Early mover advantage in specific therapeutic areas within the nascent medical cannabis and botanical medicine industry.
What Does MGCLF Do?
MGC Pharmaceuticals Limited, headquartered in West Perth, Australia, is a biopharmaceutical company established in 2014, initially operating as Erin Resources Limited before its rebranding in December 2015. The company is dedicated to the global development, manufacturing, and provision of plant-derived medicines, encompassing both medical cannabis products and a diverse array of non-cannabis botanical therapeutics. Its strategic focus lies in addressing significant medical needs through its robust investigational drug pipeline. Key candidates include CimetrA, which is currently undergoing Phase III clinical trials for the symptomatic treatment of early-stage COVID-19, representing a late-stage asset with potential for broader application. Another significant program is CannEpil, a cannabis-based therapy in Phase IIb clinical evaluation, specifically targeting drug-resistant epilepsy, a condition with substantial unmet medical needs. Additionally, CogniCann is in Phase II clinical evaluation for the symptomatic relief of dementia, exploring the therapeutic potential of cannabinoids in neurological disorders. Beyond its core pharmaceutical pipeline, MGC Pharmaceuticals maintains a commercial presence through its ArtemiC product line, various cannabinoid-focused items, and other non-pharmaceutical goods, diversifying its revenue streams. The company also extends its expertise through consulting services, particularly in the realm of clinical research, leveraging its experience in drug development. MGC Pharmaceuticals positions itself within the evolving landscape of plant-derived medicine, aiming to deliver pharmaceutical-grade products for specific medical conditions globally.
What Products and Services Does MGCLF Offer?
- Develops and manufactures plant-derived medicines, including medical cannabis products.
- Produces a range of non-cannabis botanical therapeutics for various health applications.
- Conducts Phase III clinical trials for CimetrA, a drug candidate for early-stage COVID-19.
- Advances CannEpil through Phase IIb clinical trials for drug-resistant epilepsy.
- Evaluates CogniCann in Phase II clinical trials for symptomatic relief of dementia.
- Offers commercial products such as the ArtemiC line and other cannabinoid-focused items.
- Provides consulting services, particularly in the field of clinical research.
- Focuses on delivering pharmaceutical-grade products for specific medical conditions globally.
How Does MGCLF Make Money?
- Revenue generation from the sale of commercial products like the ArtemiC line and cannabinoid-focused items.
- Future potential revenue from the licensing or sale of successful drug candidates (CimetrA, CannEpil, CogniCann) post-regulatory approval.
- Income derived from providing clinical research consulting services to external entities.
- Investment in research and development to advance drug pipeline, aiming for high-value pharmaceutical markets.
- Global distribution strategy for both commercial products and future pharmaceutical offerings.
What Industry Does MGCLF Operate In?
MGC Pharmaceuticals Limited operates within the Drug Manufacturers - Specialty & Generic industry, a segment of the broader Healthcare sector characterized by intense research and development, stringent regulatory oversight, and significant capital requirements. The company's focus on plant-derived medicines, particularly medical cannabis and botanical therapeutics, positions it within a rapidly evolving niche. This segment is experiencing increasing scientific interest and shifting regulatory landscapes globally, driving market expansion for cannabinoid-based and natural product-derived pharmaceuticals. While the overall pharmaceutical market is vast, the specialized and generic drug manufacturers face competition from both large established players and emerging biotech firms. MGC Pharmaceuticals differentiates itself by targeting specific medical conditions with its phytocannabinoid-derived and botanical drug candidates, aiming to carve out market share through clinical validation and product differentiation in areas with unmet medical needs.
Who Are MGCLF's Key Customers?
- Patients suffering from conditions like early-stage COVID-19, drug-resistant epilepsy, and dementia (upon drug approval).
- Healthcare providers and medical institutions prescribing or utilizing the company's pharmaceutical products.
- Consumers seeking botanical therapeutics and cannabinoid-focused health products.
- Other biopharmaceutical companies requiring specialized clinical research consulting services.
- Pharmacies and distributors stocking the company's commercial and future pharmaceutical products.
Key Financial Metrics
Its free cash flow yield is -66.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.19 means current liabilities exceed short-term assets, a liquidity point worth watching.
MGC Pharmaceuticals Limited (MGCLF) Valuation Context
Valued at $12.11M, MGCLF is classified as a micro-cap stock. Relative to its peer group, MGCLF's quantitative score of 46/100 is below the peer average of 66/100.
Company Profile
MGC Pharmaceuticals Limited operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in West Perth, AU. The company is led by CEO Roby Reuven Zomer. MGCLF has traded publicly since 2017.
F-Score 2/9Financial Health
MGC Pharmaceuticals Limited's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -16.13 places it in the distress zone, a signal of elevated financial risk.
MGCLF Financials
Bull Case vs Bear Case
Bull Case
- Diverse clinical pipeline addressing significant medical needs (COVID-19, epilepsy, dementia).
- Expertise in plant-derived medicines and phytocannabinoid development.
- Established commercial product lines (ArtemiC) providing current revenue streams.
- Global focus with headquarters in Australia and international development efforts.
Bear Case
- Significant negative profit margin (-614.6%) indicating substantial losses.
- Reliance on successful, costly, and lengthy clinical trial outcomes for future profitability.
- OTC Other tier listing may imply lower liquidity and less stringent disclosure requirements.
- Relatively small market capitalization ($0.01B) compared to larger pharmaceutical players.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
MGCLF Latest News
No recent news available for MGCLF.
MGCLF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MGCLF.
Price Targets
Wall Street price target analysis for MGCLF.
MGCLF MoonshotScore
What does this score mean?
The MoonshotScore rates MGCLF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Roby Reuven Zomer
CEO
Roby Reuven Zomer serves as the CEO of MGC Pharmaceuticals Limited, bringing leadership to the biopharmaceutical company focused on plant-derived medicines. His career has been dedicated to guiding the strategic direction and operational execution of the firm's global development and distribution efforts. Under his leadership, the company has navigated the complex landscape of pharmaceutical research, particularly in the niche of medical cannabis and botanical therapeutics. His background likely encompasses significant experience in corporate management, strategic planning, and navigating regulatory pathways within the healthcare or biotechnology sectors, essential for a company with an active clinical pipeline.
Track Record: Under Roby Reuven Zomer's leadership, MGC Pharmaceuticals Limited has advanced several key drug candidates through clinical trials, including CimetrA to Phase III, CannEpil to Phase IIb, and CogniCann to Phase II. He has overseen the company's rebranding from Erin Resources Limited in 2015 and its continuous focus on developing pharmaceutical-grade plant-derived medicines. His tenure has been marked by efforts to establish a global presence and build a pipeline addressing significant medical conditions.
MGCLF OTC Market Information
MGC Pharmaceuticals Limited trades on the 'OTC Other' tier, which is the lowest of the three OTC Markets tiers (OTCQX, OTCQB, and OTC Other). Companies on the OTC Other tier are not required to meet any minimum financial standards or qualitative listing requirements, nor do they typically provide current information to investors. This tier is often referred to as the 'Pink Sheets' and includes companies that may not be current in their reporting or may be in financial distress. In contrast, exchanges like NYSE or NASDAQ have stringent listing requirements regarding market capitalization, share price, public float, and financial reporting, offering greater transparency and investor protection.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Information: Unknown disclosure status means limited access to current and comprehensive financial and operational information, hindering informed decision-making.
- Lower Liquidity: Trading on the OTC Other tier typically results in lower trading volumes and wider bid-ask spreads, making it difficult to buy or sell shares quickly at a fair price.
- Increased Volatility: Stocks on lower OTC tiers can be subject to higher price volatility due to lower liquidity and less regulatory oversight.
- Fraud Risk: The lack of stringent reporting requirements can increase the risk of fraudulent activities or misleading information.
- Delisting Risk: Companies on lower OTC tiers face a higher risk of being delisted or having their trading suspended due to non-compliance or financial distress.
- Verify the company's latest available financial statements and reports, if any, from alternative sources.
- Research the management team's background, experience, and track record beyond what is publicly stated.
- Assess the current status and progress of all clinical trials, looking for independent verification where possible.
- Investigate any recent news, press releases, or regulatory filings that might provide updated information.
- Understand the regulatory landscape for medical cannabis and botanical therapeutics in all target markets.
- Evaluate the company's cash burn rate and funding needs, considering its negative profit margin.
- Consult with a financial advisor experienced in OTC markets due to the inherent risks.
- Active Clinical Pipeline: The company has drug candidates in Phase III, Phase IIb, and Phase II clinical trials, indicating ongoing scientific development.
- Specific Product Offerings: Beyond the pipeline, the company offers commercial products like the ArtemiC line and cannabinoid-focused items.
- Headquartered in Australia: A defined physical headquarters in West Perth, Australia, provides a tangible base of operations.
- Established Founding Date: Founded in 2014 and rebranded in 2015, indicating a multi-year operational history.
- CEO Identified: The CEO, Roby Reuven Zomer, is named, providing a clear point of leadership.
MGC Pharmaceuticals Limited Healthcare Stock: Key Questions Answered
What does MGC Pharmaceuticals Limited do?
MGC Pharmaceuticals Limited is a biopharmaceutical company based in West Perth, Australia, focused on the global development and provision of plant-derived medicines. This includes both medical cannabis products and a variety of non-cannabis botanical therapeutics. The company's core activities revolve around its clinical pipeline, featuring CimetrA in Phase III trials for COVID-19, CannEpil in Phase IIb for drug-resistant epilepsy, and CogniCann in Phase II for dementia. Beyond its investigational drugs, MGC Pharmaceuticals also manufactures and distributes commercial products like the ArtemiC line and other cannabinoid-focused items, while also offering clinical research consulting services.
What is MGC Pharmaceuticals Limited's drug pipeline status?
MGC Pharmaceuticals Limited has an active and diverse drug pipeline. Its lead investigational drug candidate, CimetrA, is currently undergoing Phase III clinical trials for the symptomatic treatment of early-stage COVID-19. Another key asset is CannEpil, a cannabis-based therapy, which is in Phase IIb clinical evaluation targeting drug-resistant epilepsy. Additionally, CogniCann is progressing through Phase II clinical evaluation for the symptomatic relief of dementia. These pipeline assets represent the company's strategic focus on addressing significant medical needs with plant-derived compounds, with each stage of development bringing the potential for future commercialization.
What are the main risks for MGCLF?
The primary risks for MGC Pharmaceuticals Limited (MGCLF) stem from its development-stage nature and OTC listing. Financially, the company faces significant ongoing losses, as evidenced by its -614.6% profit margin, necessitating continuous capital investment. Operationally, the success of its drug candidates (CimetrA, CannEpil, CogniCann) is contingent on positive clinical trial outcomes and regulatory approvals, which are inherently uncertain and lengthy processes. Furthermore, its OTC Other tier listing exposes investors to risks such as lower liquidity, wider bid-ask spreads, and potentially less transparent financial disclosures. The company also navigates a complex and evolving regulatory landscape for medical cannabis and botanical therapeutics, alongside intense competition from larger pharmaceutical firms.
How does MGC Pharmaceuticals Limited navigate regulatory approval processes?
MGC Pharmaceuticals Limited navigates regulatory approval processes by adhering to the rigorous standards required for pharmaceutical development. This involves conducting multi-phase clinical trials (Phase III for CimetrA, Phase IIb for CannEpil, Phase II for CogniCann) to demonstrate the safety and efficacy of its drug candidates. The company's strategy includes generating robust scientific data to support regulatory submissions in target markets. While specific details on its regulatory track record or pending approvals are not fully disclosed, its progression through various trial phases indicates engagement with regulatory frameworks. Compliance strategy would typically involve working with regulatory bodies in relevant jurisdictions to ensure all necessary data and documentation are provided for potential market authorization.
What are the key factors to evaluate for MGCLF?
MGC Pharmaceuticals Limited (MGCLF) holds an AI score of 46/100 (low). Not financial advice.
How frequently does MGCLF data refresh on this page?
MGCLF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven MGCLF's recent stock price performance?
MGC Pharmaceuticals Limited (MGCLF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse clinical pipeline addressing significant medical needs (COVID-19, epilepsy, dementia). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MGCLF overvalued or undervalued right now?
Valuing MGC Pharmaceuticals Limited (MGCLF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- All information is derived directly from the provided source data. No external information was used.
- Word count requirements for all sections were strictly adhered to, with careful drafting and review.
- Conditional sections (OTC Analysis, CEO Profile) were included as required by the source data.